ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors

The expected combined toxicity is often low for anti-HER2 monoclonal antibodies. For most scenarios with CDK4/6, PARP, or mTOR inhibitors, exercising caution is recommended.

Authors

Institutions

Publication Details

Journal
Radiotherapy and Oncology
Published
2025-12-11
DOI
https://doi.org/10.1016/j.radonc.2025.111330
Citations
1
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
1.52

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors

Carmen Criscitiello, Diogo Martins-Branco, Bharti Devnani, Evert S.M. van Aken et al.
1 citations
Radiotherapy and Oncology
Advanced Breast Cancer Therapies
1.52
article

ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors

Carmen Criscitiello, Diogo Martins-Branco, Bharti Devnani, Evert S.M. van Aken, Corrie A.M. Marijnen, Antonin Lévy, George E. Pentheroudakis, Séan M. O’Cathail, Monique C. de Jong, Nadia Harbeck, Emmanouil Fokas, Gábor Liposits, Dario Trapani, Claus Belka, P Boot, Ilaria Colombo, Ajeet Kumar Gandhi, Marcel Verheij, Florian Lordick, Dirk De Ruysscher, Anne Hansen Ree, Umberto Ricardi, Jorge Barriuso, Maximilian Niyazi, Gerben Borst, Arsela Prelaj, Stephanie Kroeze, Evandro de Azambuja, I. L. Ray-Coquard, Paolo Tarantino, Luís Castelo-Branco, Ewa Szutowicz
article en
1 citations

Abstract

The expected combined toxicity is often low for anti-HER2 monoclonal antibodies. For most scenarios with CDK4/6, PARP, or mTOR inhibitors, exercising caution is recommended.

Radiotherapy and OncologyVol. 215
Université Claude Bernard Lyon 1 (FR), Université Libre de Bruxelles (BE), Radboud University Nijmegen (NL), All India Institute of Medical Sciences Jodhpur (IN), Innlandet Hospital Trust (NO), Université Paris-Saclay (FR), Manchester Academic Health Science Centre (GB), European Society for Medical Oncology (CH), Akershus University Hospital (NO), Institut Jules Bordet (BE), Institut Gustave Roussy (FR), Cork University Hospital (IE), Radboud University Medical Center (NL), LMU Klinikum (DE), Research Institute Hospital 12 de Octubre (ES), Integrated Oncology (United States) (US), Ente Ospedaliero Cantonale (CH), Hospital Universitario 12 De Octubre (ES), Centre Léon Bérard (FR), Dana-Farber Cancer Institute (US), Breast Center (CH), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NL), University Children's Hospital Tübingen (DE), Dr. Ram Manohar Lohia Institute of Medical Sciences (IN), The Christie NHS Foundation Trust (GB), Erasmus MC Cancer Institute (NL), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Kantonsspital Aarau (CH), University of Turin (IT), European Institute of Oncology (IT), Gdańsk Medical University (PL), University of Glasgow (GB), Ludwig-Maximilians-Universität München (DE), Leipzig University (DE)
European Society for Medical Oncology
Openalex Percentile: Top 12%
Advanced Breast Cancer Therapies
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.